Product Description
Sotagliflozin is an SGLT2 inhibitor that also inhibits gastrointestinal SGLT1. Inhibition of SGLT2 increases urinary glucose excretion, whereas inhibition of SGLT1 appears to delay glucose absorption and reduce postprandial glucose. (Sourced from: https://www.nejm.org/doi/full/10.1056/NEJMoa2030186)
Mechanisms of Action: SGLT1 Inhibitor,SGLT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovakia | Sweden | United States
Approved Indications: None
Known Adverse Events: None
Company: Lexicon
Company Location: THE WOODLANDS TX 77381
Company CEO: Lonnel Coats
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Denmark, Finland, Netherlands, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Cardiomyopathies|Cardiomyopathy, Hypertrophic|Diabetic Nephropathy|Heart Failure, Chronic|Kidney Failure, Chronic|Type 1 Diabetes
Phase 2: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUGARNSALT | P3 |
Recruiting |
Diabetic Nephropathy|Kidney Failure, Chronic|Heart Failure, Chronic|Type 1 Diabetes |
2028-12-01 |
|
| SONATA-HCM | P3 |
Recruiting |
Cardiomyopathy, Hypertrophic|Cardiomyopathies |
2026-07-01 |
|
| SOPHIST | P2 |
Not yet recruiting |
Type 1 Diabetes|Heart Failure |
2026-06-01 |
|
| ASPIRE | P2 |
Not yet recruiting |
Type 1 Diabetes|Diabetic Nephropathy |
2025-03-01 |